Fig. 3.

Mean absolute PASI. During the therapy with brodalumab, the mean PASI decreased from 16.1 (± 5.0) at baseline to 1.0 (± 3.4) at week 12. After 52 weeks of treatment, the mean PASI was 0.5 (± 1.2). Concerning the individual subgroups, efficacy of brodalumab, evaluated on the based of absolute PASI change, was observed in both biologic-naïve patients and those previously treated by anti-TNFα, anti-IL-17A, or IL-23/12 or IL-23. BL baseline, Bx biologic, IL interleukin, PASI Psoriasis Area Severity Index, TNFα tumor necrosis factor alpha